JOHNSON & JOHNSON is 117.4x more valuable than Amneal Pharmaceuticals, Inc. by market capitalization ($573.98 B vs $4.89 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AMRX | JNJ |
|---|---|---|
| Market cap | $4.89 B | $573.98 B |
| US-listed rank | #1397 | #20 |
| Revenue (latest FY) | $3.02B | $94.19B |
| Net income (latest FY) | $72.06M | $26.80B |
| Net margin | 2.4% | 28.5% |
| P/E (trailing FY) | 67.8 | 21.4 |
| SEC filings | 664 | 984 |
JOHNSON & JOHNSON is 117.4x more valuable than Amneal Pharmaceuticals, Inc. by market capitalization ($573.98 B vs $4.89 B).
In their latest fiscal years, Amneal Pharmaceuticals, Inc. reported $3.02B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Amneal Pharmaceuticals, Inc. and JOHNSON & JOHNSON, or browse the full rankings.